AVEO Pharmaceuticals, Inc. (AVEO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

5.86+0.21 (+3.72%)

At close: 4:00PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	5.65
Open	5.68
Bid	5.86 x 800
Ask	6.05 x 900
Day's Range	5.68 - 5.99
52 Week Range	2.23 - 10.71
Volume	380,793
Avg. Volume	537,334

Market Cap	151.237M
Beta (5Y Monthly)	1.56
PE Ratio (TTM)	N/A
EPS (TTM)	-0.23
Earnings Date	Aug 10, 2020
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	12.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Zacks
Increased Earnings Estimates Seen for AVEO Pharmaceuticals (AVEO): Can It Move Higher?
AVEO Pharmaceuticals (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
- Jabil (JBL) in Focus: Stock Moves 6.5% Higher
  Zacks
- Top Ranked Income Stocks to Buy for September 24th
  Zacks
Business Wire
AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIVO-3 is the Company’s pivotal Phase 3 trial comparing tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, to sorafenib in third and fourth line renal cell carcinoma (RCC). The article, titled "Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma," is available online first via this link.
Zacks
AVEO's Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals.